Bone marrow transplantation (BMT) for acute nonlymphoid leukemia (ANLL) in first remission

A. Bacigalupo, F. Frassoni, M. T. Van Lint, P. A. Pittaluga, G. Piaggio, M. Repetto, M. Congiu, V. Vitale, D. Scarpati, R. Corvò, G. Ricci, G. F. Adami, R. Adami, G. Lercari, D. Occhini, A. M. Marmont

Research output: Contribution to journalArticlepeer-review


20 patients with acute nonlymphoid leukemia (ANLL) in first remission were given cyclophosphamide, 120 mg/kg, followed by total body irradiation (TBI) and an HLA-identical allogeneic marrow transplant (BMT). TBI was delivered in a single dose (10 Gy on day -1) in 2 patients, or in fractionated doses (3.3 rad/day on days -3, -2, -1) in 18 patients. The median age of patients was 22 years (range 2-44). Median time from remission to BMT was 5 months (range 1-12). 5 patients died of transplant-related toxicity (graft-versus-host disease with or without interstitial pneumonia) and 15 are alive 7-77 months post-BMT (median 20). The actuarial 72 months survival is 73%. There has been one relapse in a 2-year-old child, 4 months post-BMT, in the marrow and in the testis. The 72-month actuarial disease-free survival is 68%. The actuarial probability of relapse is 7%. This study indicates that a high proportion of ANLL patients treated in first remission with fractionated TBI and allogeneic marrow transplantation can become long-term disease-free survivors.

Original languageEnglish
Pages (from-to)23-26
Number of pages4
JournalActa Haematologica
Issue number1
Publication statusPublished - 1985


  • Bone marrow transplantation
  • Leukemia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Bone marrow transplantation (BMT) for acute nonlymphoid leukemia (ANLL) in first remission'. Together they form a unique fingerprint.

Cite this